For the roughly 7 million Americans living with alopecia areata, a visit to the pharmacy has long meant confronting a dispiriting reality: no FDA-approved treatment existed. That changed when the U.S. Food and Drug Administration approved baricitinib — sold under the brand name Olumiant — as the first systemic treatment for severe alopecia areata, an autoimmune disorder in which the body’s immune system attacks hair follicles.
At a glance
- Alopecia areata treatment: Baricitinib is the first FDA-approved systemic therapy for severe alopecia areata, an autoimmune condition affecting about 7 million people in the United States.
- Clinical trial results: In trials, one in three patients with severe alopecia areata regrew enough hair to achieve 80% or more scalp coverage — with nearly half of participants starting the trials with no scalp hair at all.
- JAK inhibitor: Baricitinib belongs to a class of drugs called Janus kinase inhibitors, originally developed for rheumatoid arthritis, that researchers have been studying as treatments for a range of skin diseases for over a decade.
What baricitinib approval means for patients
Alopecia areata goes well beyond scalp hair. The disease can strip away eyebrows, eyelashes, facial hair, and body hair, and it carries a significant psychological toll. Previous treatments for severe cases were largely ineffective, and the medicines that showed promise — JAK inhibitors — were not approved for this use, making insurance coverage difficult to obtain.
FDA approval changes that equation directly. Dr. Brett King, an associate professor of dermatology at Yale Medical School who led clinical research on the drug with pharmaceutical company Eli Lilly and Company, explained that approval opens two practical doors at once. “When a medicine is approved for treatment of a disease, doctors feel more comfortable prescribing the medicine for that purpose,” King said. “Therefore, FDA approval will empower and enable health care providers to treat patients with severe alopecia areata.” It also unlocks insurance coverage, removing a major barrier to access.
Olumiant is taken as a once-daily pill — a meaningful practical advantage for patients managing a chronic condition.
A decade of research rooted in one patient’s story
The approval caps more than ten years of work that began with a single case in 2013 C.E. King remembers treating a patient who had almost no scalp hair, was missing his eyebrows, eyelashes, and facial hair, and was also dealing with psoriasis across his body. He gave the patient tofacitinib — another JAK inhibitor — on an exploratory basis.
“Not long after he started taking tofacitinib, his hair started to grow,” King recalled. He published those results shortly afterward, a paper that helped redirect scientific attention toward JAK inhibitors as a serious avenue for treating skin autoimmune diseases.
Since then, King has investigated JAK inhibitors across a range of intractable skin conditions, including eczema, vitiligo, granuloma annulare, sarcoidosis, and erosive lichen planus. The baricitinib trials with Eli Lilly represent the culmination of that research arc. Results from those trials were published in the New England Journal of Medicine.
How the drug works
JAK inhibitors work by blocking specific enzymes — Janus kinases — that play a key role in the inflammatory signaling pathways the immune system uses to attack hair follicles in alopecia areata. By interrupting that signaling, the drug allows follicles to resume normal hair production.
The mechanism is the same one that made JAK inhibitors effective for rheumatoid arthritis. King’s insight was that the underlying inflammatory pathway is similar enough in certain skin diseases to make these drugs worth testing well beyond their original indication. That hypothesis has now produced an FDA-approved therapy.
Real results, with important caveats
One in three patients in the trials achieved 80% or more scalp coverage — a result that is clinically significant given how severe the starting conditions were. Improvements were also seen in patients with significant eyebrow and eyelash loss.
Still, two in three patients did not reach that threshold, and the drug does not work equally well for everyone. As with most autoimmune therapies, baricitinib carries potential side effects including immune suppression, and its long-term safety profile will continue to be monitored as it reaches broader use. Access, while improved by approval, will still depend on individual insurance plans, and not all patients with alopecia areata — which ranges in severity — will qualify for this treatment under current guidelines. The approval covers severe cases specifically.
What the approval does guarantee is a starting point: a legitimate, evidence-backed option where none existed before. For a disease that has gone without approved systemic treatment for this long, that is a meaningful shift.
Read more
For more on this story, see: Good News Network — FDA approves first alopecia drug
For more from Good News for Humankind, see:
- Alzheimer’s risk cut in half by drug in landmark prevention trial
- Indigenous land rights win at COP30 covers 160 million hectares
- The Good News for Humankind archive on global health
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
